A-Share Listed Biological Products Companies - Profiles and Financial Data

In China, biological products include: bacterial vaccines (containing toxoid), viral vaccines, antitoxin and antiserum, blood products, cytokine, growth factors, enzyme, in vivo and in vitro diagnostic products, and other biological active preparations.

According to CRI, fast economic growth and residents' increasing income have pushed up people's medical expenses. China's biological products market outperforms the global average. In China, the market size exceeded CNY 130 billion in 2016, but its share in the pharmaceutical market was less than 10%, far below that in developed countries.

In the Thirteenth Five-Year Plan (2016-2020), biotechnological pharmaceuticals, new vaccines, new cell therapy preparations and other innovative pharmaceuticals were listed among the priorities of the biomedicine industry. It is expected that in the next few years, biotechnological advances and favorable policies will facilitate fast growth of the biological product industry.

In this report, CRI analyzes 38 biological products manufacturers listed in A-share market in China.

The report is composed of two parts: the first part is enterprise profiles and the second part is the operation status of these enterprises in the recent decade (presently 2006 to 2016, we will update it to the latest as time goes by).

The operation status is demonstrated from the following perspectives: (1)financial indexes, such as earnings per share, book value per share (BPS), sales per share, net cash flow per share, return on net worth and debt to asset ratio; (2) indexes on the income statement, such as revenue, operating profit, net profit and EBIT; (3) indexes on the income statement, such as revenue, operating profit, net profit and EBIT; (4) indexes on the balance sheet, such as liquid asset, fixed asset, current liability, non-current liability, capital reserve and shareholders' equity.

Financial Indexes

• Earnings per Share


• Book Value per Share (BPS)


• Sales per Share (SPS)


• Net Cash Flow per Share from Operations


• Net Cash Flow per Share (CNY)


• Return on Net Worth


• Net Profit Margin on Total Assets


• Return on Invested Capital (ROIC) (%)


• Gross Profit Margin on Sales (%)


• Net Profit Margin on Sales (%)


• EBIT Margin (%)


• EBITDA Margin (%)


• Debt to Asset Ratio (%)


• Total Asset Turnover (times)


• Cash/Operating Income Received from Sales of Goods or Services


• YOY Growth Rate of Operating Revenue (%)


• YOY Growth Rate of Operating Profit (%)


• YOY Growth Rate of Net Profit Attributable to Shareholders of Parent Company (%)

Summary of Income Statement

• Gross Revenue (CNY, million)


• Total Operating Costs (CNY, million)


• Revenue (CNY, million)


• Operating Profit (CNY, million)


• Total Profit (CNY, million)


• Net Profit (CNY, million)


• Net Profit Attributable to Shareholders of Parent Company (CNY, million)


• Non-recurring Items (CNY, million)


• Net Profit Deducting Non-recurring Items (CNY, million)


• R&D Costs (CNY, million)


• Earnings Before Interest and Tax (EBIT) (CNY, million)


• Earnings Before Interest, Taxes, Depreciation and Amortization (EBITDA) (CNY, million)

Summary of Balance Sheet

• Liquid Asset (CNY, million)


• Fixed Asset (CNY, million)


• Long-term Equity Investment


• Total Assets (CNY, million)


• Liquid Liability (CNY, million)


• Non-current Liability (CNY, million)


• Total Liability (CNY, million)


• Capital Reserve (CNY, million)


• Surplus Reserve (CNY, million)


• Undistributed Profit (CNY, million)


• Shareholders' Equity (CNY, million)


• Equity Attributable to Shareholders of Parent Company (CNY, million)

Summary of Cash Flow Statement

• Cash Received from Sales of Goods and Services (CNY, million)


• Cash Flow from Operations (CNY, million)


• Cash Paid to Purchase Fixed Assets, Intangible Assets and Other Long-term Assets (CNY, million)


• Cash Paid for Investments (CNY, million)


• Cash Flow from Investments (CNY, million)


• Cash Received from Investors (CNY, million)


• Cash Received from Borrowings (CNY, million)


• Cash Flow from Financing (CNY, million)


• Net Increase of Cash and Cash Equivalents (CNY, million)


• Cash and Cash Equivalents, End of Period (CNY, million)


• Depreciation and Amortization (CNY, million)